** Shares of the New York-based drug developer IN8bio INAB.O rises 17.5% to 31 cents
** Co says early-stage trial showed its experimental cancer therapy helped all 9 patients with a type of blood cancer remain in complete remission
** Co's therapy, INB-100, also helped increase survival rates of patients compared to historical data and the time they lived without their cancer worsening
** INAB was testing its therapy to treat acute myeloid leukemia, a cancer of the blood and bone marrow
** INB-100 uses gamma-delta T cells, that are rarely found in secondary lymphoid organs and play a role in helping control cancer activity, to target the disease
** Patients treated with INB-100 also showed prolonged and durable decrease in symptoms of their cancer beyond one year
** In the last 12 months, INAB has fallen 70.27%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。